These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 18997093

  • 21. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.
    Jeong JH, Chun YS, Kim ES, Kim JC.
    Cornea; 2011 Oct; 30(10):1071-7. PubMed ID: 21775887
    [Abstract] [Full Text] [Related]

  • 22. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP, Bhat PV, Foster CS.
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [Abstract] [Full Text] [Related]

  • 23. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY, Kim MK, Wee WR.
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [Abstract] [Full Text] [Related]

  • 24. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR.
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [Abstract] [Full Text] [Related]

  • 25. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
    Chen WL, Chen YM, Chu HS, Lin CT, Chow LP, Chen CT, Hu FR.
    PLoS One; 2014 Oct; 9(4):e94205. PubMed ID: 24714670
    [Abstract] [Full Text] [Related]

  • 26. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V, Küçükerdönmez C, Akova YA, Çolak A, Karalezli A.
    Ophthalmic Res; 2012 Oct; 48(3):118-23. PubMed ID: 22538642
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
    Ko BY, Kim YS, Baek SG, Lee GW, Kim JM, Jean WS, Lee NS, Kang J.
    Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
    [Abstract] [Full Text] [Related]

  • 28. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
    Gore A, Horwitz V, Cohen M, Gutman H, Cohen L, Gez R, Kadar T, Dachir S.
    Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
    [Abstract] [Full Text] [Related]

  • 29. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
    Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F.
    Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
    [Abstract] [Full Text] [Related]

  • 30. Subconjunctival bevacizumab for corneal neovascularization.
    Erdurmus M, Totan Y.
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
    [Abstract] [Full Text] [Related]

  • 31. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
    Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M.
    Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
    [Abstract] [Full Text] [Related]

  • 32. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
    Park JH, Joo CK, Chung SK.
    Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
    [Abstract] [Full Text] [Related]

  • 33. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
    Ahmed A, Berati H, Nalan A, Aylin S.
    Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
    [Abstract] [Full Text] [Related]

  • 34. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
    Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E.
    Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
    [Abstract] [Full Text] [Related]

  • 35. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY.
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC, Kang IS, Lee SH, Yoon KC.
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [Abstract] [Full Text] [Related]

  • 37. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab.
    Chu HS, Chen TC, Hu FR, Chen WL.
    Cornea; 2013 Nov; 32(11):1446-53. PubMed ID: 24055900
    [Abstract] [Full Text] [Related]

  • 38. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
    Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P, Tübingen Bevacizumab Study Group.
    Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model.
    Gal-Or O, Livny E, Sella R, Nisgav Y, Weinberger D, Livnat T, Bahar I.
    Cornea; 2016 Jul; 35(7):991-6. PubMed ID: 27124775
    [Abstract] [Full Text] [Related]

  • 40. Effect of Conbercept on Corneal Neovascularization in a Rabbit Model.
    Du L, Sun J, Liu J, Xu N, Liu M, Wu X.
    Semin Ophthalmol; 2023 Oct; 38(7):670-678. PubMed ID: 37058000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.